Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study
Authors:
Open Access
- 23 December 2023
- journal article
- research article
- Published by Elsevier in European Urology Oncology
- Vol. 7 (4) , 906-913
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Dainippon Sumitomo Pharma
This publication has 25 references indexed in Scilit:
- Intermittent Androgen Suppression for Rising PSA Level after RadiotherapyNew England Journal of Medicine, 2012
- An update on the use of gonadotropin-releasing hormone antagonists in prostate cancerTherapeutic Advances in Urology, 2011
- Intermittent Androgen Suppression in Prostate Cancer: Testosterone Levels and its ImplicationThe Journal of Sexual Medicine, 2011
- The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancerBJU International, 2008
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancerEuropean Journal of Cancer, 2006
- Time course of serum testosterone and luteinizing hormone levels after cessation of long‐term luteinizing hormone‐releasing hormone agonist treatment in patients with prostate cancerThe Prostate, 2005
- Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancerExpert Opinion on Pharmacotherapy, 2004
- Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2002
- GONADOTROPIN-RELEASING HORMONE AND ITS ANALOGSAnnual Review of Medicine, 1994